Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/dth.14463 http://scihub22266oqcxt.onion/10.1111/dth.14463 33112053!?!33112053 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33112053&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Dermatol+Ther 2021 ; 34 (1): e14463 Nephropedia Template TP {{tp|p=33112053|t=2021. Cutaneous lymphomas and COVID-19: What is known so far?|pdf=|usr=}}{{33112053}} gab.com Text Cutaneous lymphomas and COVID-19: What is known so far JO: Dermatol Ther http://www.kidney.de/pget.php?&tw=1&pmid=33112053 #FOAvip The Coronavirus disease 2019 (COVID-19) pandemic spreads quickly all over the world. There are no sufficient data in the literature about COVID-19 infection and cutaneous lymphomas. This review sheds the light on what is known so far about COVID-19 with a cutaneous lymphoma perspective. Cutaneous T-cell lymphoma (CTCL) diagnosis does not represent a predisposing factor to viral infections and most of CTCL patients have indolent disease. However, physicians should be cautious with patients with aggressive primary cutaneous lymphomas and advanced CTCL. Different treatment strategies for cutaneous lymphomas should be taken into consideration during the COVID-19 pandemic. Thus, it is highly needed to estimate the benefit-to-risk ratio on a case-by-case basis. Twit Text FOAVip Cutaneous lymphomas and COVID-19: What is known so far ????Dermatol Ther http://www.kidney.de/pget.php?&tw=1&pmid=33112053 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33112053 #FOAvip English Wikipedia <ref>{{Cite pmid|33112053}}</ref> Cutaneous lymphomas and COVID-19: What is known so far? #MMPMID33112053 Elmasry MF; Youssef R; Elbendary A; Helmy K; Abdelkader HA Dermatol Ther 2021[Jan]; 34 (1): e14463 PMID33112053show ga The Coronavirus disease 2019 (COVID-19) pandemic spreads quickly all over the world. There are no sufficient data in the literature about COVID-19 infection and cutaneous lymphomas. This review sheds the light on what is known so far about COVID-19 with a cutaneous lymphoma perspective. Cutaneous T-cell lymphoma (CTCL) diagnosis does not represent a predisposing factor to viral infections and most of CTCL patients have indolent disease. However, physicians should be cautious with patients with aggressive primary cutaneous lymphomas and advanced CTCL. Different treatment strategies for cutaneous lymphomas should be taken into consideration during the COVID-19 pandemic. Thus, it is highly needed to estimate the benefit-to-risk ratio on a case-by-case basis. |*COVID-19[MESH] |*Lymphoma, T-Cell, Cutaneous/diagnosis/epidemiology/therapy[MESH] |*Skin Neoplasms/diagnosis/epidemiology/therapy[MESH] |Humans[MESH] |Pandemics[MESH]Cutaneous lymphomas and COVID-19: What is known so far?(epmc).pdf DeepDyve Pubget Overpricing